Table of Content

1. Key Insights

2. Hepatorenal Syndrome (HRS) Market Overview at a Glance
2.1. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2017
2.2. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2030

3. Executive Summary

4. Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Etiology and Risk Factors
4.4. Pathophysiology
4.5. Precipitating Factors
4.6. Classification and Diagnosis Criteria of Hepatorenal Syndrome

5. Epidemiology and Patient Population
5.1. Key Findings

6. Country-wise Epidemiology of Hepatorenal Syndrome: 7MM

7. Assumptions and rationale
7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM
7.2. The United States
7.2.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States
7.2.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States
7.2.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United States
7.3. EU5 Countries
7.3.1. Germany
7.3.2. Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany
7.3.3. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany
7.3.4. Type-specific Incident of Hepatorenal Syndrome (HRS) in Germany
7.4. France
7.4.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in France
7.4.2. Diagnosed incidence of Hepatorenal Syndrome (HRS) in France
7.4.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in France
7.5. Italy
7.5.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy
7.5.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy
7.5.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Italy
7.6. Spain
7.6.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain
7.6.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain
7.6.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Spain
7.7. United Kingdom
7.7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom
7.7.4. Japan
7.7.5. Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan
7.7.6. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan
7.7.7. Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan

8. Treatment and Management
8.1. Management of Type I (HRS-AKI)
8.1.1. The new algorithm for the management of AKI HRS and implications for therapy
8.2. Management of Type-II (HRS-CKD)

9. Unmet Needs

10. Organizations

11. Patient Journey

12. Emerging Therapies
12.1. Key cross competition
12.2. Terlipressin: Mallinckrodt
12.2.1. Drug Description
12.2.2. Product Developmental Activities
12.2.3. Other Developmental Activities
12.2.4. Clinical Development
12.2.5. Clinical Trials Information
12.2.6. Safety and Efficacy
12.2.7. Product Profile
12.3. BIV201: BioVie
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Product Profile

13. Other Potential Therapies
13.1. Ifetroban: Cumberland Pharmaceuticals
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Clinical Trials Information
13.1.5. Product Profile

14. Hepatorenal Syndrome (HRS): Seven Major Market Analysis
14.1. Key Findings
14.2. Market Size of Hepatorenal Syndrome (HRS) in 7MM

15. Seven Major Market Outlook
15.1. The United States Market Size
15.1.1. Total Market Size of Hepatorenal Syndrome (HRS) in the United States
15.1.2. Market Size of Hepatorenal Syndrome (HRS) by Therapies in the United States
15.2. Germany
15.2.1. The total market size of Hepatorenal Syndrome (HRS) in Germany
15.2.2. Market size of Hepatorenal Syndrome (HRS) by Therapies in Germany
15.3. France
15.3.1. The total market size of Hepatorenal Syndrome (HRS) in France
15.3.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in France
15.4. Italy
15.4.1. The total market size of Hepatorenal Syndrome (HRS) in Italy
15.4.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Italy
15.5. Spain
15.5.1. Total Market Size of Hepatorenal Syndrome (HRS) in Spain
15.5.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Spain
15.6. United Kingdom
15.6.1. The total market size of Hepatorenal Syndrome (HRS) in the United Kingdom
15.6.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in the UK
15.7. Japan
15.7.1. The total market size of Hepatorenal Syndrome (HRS) in Japan
15.7.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. Market Access and Reimbursement

19. SWOT Analysis for HRS

20. Case studies
20.1. A Case of Type I Hepatorenal Syndrome Treated with Vasopressin
20.2. Hepatorenal Syndrome: Case Representation
20.3. A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion
21. Bibliography
22. Appendix
22.1. Report Methodology
22.2. Reference
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight



List of Figures


Figure 1: Symptoms of HRS
Figure 2: New Pathophysiological hypothesis of acute decompensation and the development of organ dysfunction in patients with cirrhosis
Figure 3: Mechanisms of renal injury potentially involved in HRS-AKI in patients with cirrhosis
Figure 4: Role of a precipitating factor in HRS
Figure 5: Criteria for the diagnosis of AKI based on absolute or percentage increase of serum creatinine-based on the time of initial presentation (T0)
Figure 6: Criteria for the diagnosis of HRS-NAKI based on the time of initial presentation (T0)
Figure 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017–2030)
Figure 8: Total Incident Cases of Hepatorenal Syndrome in the United States (2017–2030)
Figure 9: Diagnosed Incidence of Hepatorenal Syndrome in the United States (2017–2030)
Figure 10: Type-specific Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the US (2017–2030)
Figure 11: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Figure 12: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Figure 13: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Figure 14: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017–2030)
Figure 15: Diagnosed incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)
Figure 16: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)
Figure 17: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Figure 18: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Figure 19: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Figure 20: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Figure 21: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Figure 22: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Figure 23: Total Incident Cases of Hepatorenal Syndrome in the UK (2017–2030)
Figure 24: Diagnosed Incidence of Hepatorenal Syndrome in the UK (2017–2030)
Figure 25: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017–2030)
Figure 26: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Figure 27: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Figure 28: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Figure 29: Algorithm for the management of AKI in patients with cirrhosis.
Figure 30: Unmet Needs
Figure 31: Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)
Figure 32: Market Size of Hepatorenal Syndrome (HRS) in the US, USD Millions (2017–2030)
Figure 33: Market Size of Hepatorenal Syndrome (HRS) in the US by therapies, USD Millions (2017–2030)
Figure 34: Market Size of Hepatorenal Syndrome (HRS) in Germany, USD Millions (2017–2030)
Figure 35: Market Size of Hepatorenal Syndrome (HRS) in Germany by therapies, USD Millions (2017–2030)
Figure 36: Market Size of Hepatorenal Syndrome (HRS) in France, USD Millions (2017–2030)
Figure 37: Market Size of Hepatorenal Syndrome (HRS) in France by therapies, USD Millions (2017–2030)
Figure 38: Market Size of Hepatorenal Syndrome (HRS) in Italy, USD Millions (2017–2030)
Figure 39: Market Size of Hepatorenal Syndrome in Italy by therapies, USD Millions (2017–2030)
Figure 40: Market Size of Hepatorenal Syndrome (HRS) in Spain, USD Millions (2017–2030)
Figure 41: Market Size of Hepatorenal Syndrome (HRS) in Spain by therapies, USD Millions (2017–2030)
Figure 42: Market Size of Hepatorenal Syndrome (HRS) in the UK, USD Millions (2017–2030)
Figure 43: Market Size of Hepatorenal Syndrome (HRS) in the UK by therapies, USD Millions (2017–2030)
Figure 44: Market Size of Hepatorenal Syndrome (HRS) in Japan, USD Millions (2017–2030)
Figure 45: Market Size of Hepatorenal Syndrome (HRS) in Japan by therapies, USD Millions (2017–2030)
Figure 46: Market Drivers
Figure 47: Market Barriers


List of Tables


Table 1: New classification of HRS subtypes.
Table 2: New diagnostic criteria for HRS-AKI
Table 3: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017–2030)
Table 4: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States (2017–2030)
Table 5: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States (2017–2030)
Table 6: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the US (2017–2030)
Table 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Table 8: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Table 9: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)
Table 10: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017–2030)
Table 11: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)
Table 12: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)
Table 13: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Table 14: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Table 15: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)
Table 16: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Table 17: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Table 18: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)
Table 19: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017–2030)
Table 20: Diagnosed Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017–2030)
Table 21: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017–2030)
Table 22: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Table 23: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Table 24: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)
Table 25: Key cross competition - Emerging Therapies
Table 26: Terlipressin, Clinical Trial Description, 2021
Table 27: Ifetroban, Clinical Trial Description, 2021
Table 28: Market Size of Hepatorenal Syndrome (HRS) in 7MM in USD Million (2017–2030)
Table 29: The US Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)
Table 30: US Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)
Table 31: Market Size of Hepatorenal Syndrome (HRS) in Germany, USD Millions (2017–2030)
Table 32: Germany Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 33: Market Size of Hepatorenal Syndrome (HRS) associated in France, USD Millions (2017–2030)
Table 34: France Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 35: Italy Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 36: Italy Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 37: Market Size of Hepatorenal Syndrome (HRS) in Spain, USD Millions (2017–2030)
Table 38: Spain Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 39: Market Size of Hepatorenal Syndrome (HRS) in the UK, USD Millions (2017–2030)
Table 40: UK Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)
Table 41: Market Size of Hepatorenal Syndrome (HRS) in Japan, USD Millions (2017–2030)
Table 42: Japan Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)